U.S. markets close in 1 hour 17 minutes
  • S&P 500

    3,809.00
    +23.62 (+0.62%)
     
  • Dow 30

    30,991.27
    +215.84 (+0.70%)
     
  • Nasdaq

    11,077.29
    +48.56 (+0.44%)
     
  • Russell 2000

    1,719.08
    +11.09 (+0.65%)
     
  • Crude Oil

    108.14
    +2.38 (+2.25%)
     
  • Gold

    1,808.60
    +1.30 (+0.07%)
     
  • Silver

    19.82
    -0.54 (-2.64%)
     
  • EUR/USD

    1.0429
    -0.0055 (-0.52%)
     
  • 10-Yr Bond

    2.8880
    -0.0840 (-2.83%)
     
  • GBP/USD

    1.2096
    -0.0080 (-0.65%)
     
  • USD/JPY

    135.2650
    -0.4630 (-0.34%)
     
  • BTC-USD

    19,475.97
    +424.49 (+2.23%)
     
  • CMC Crypto 200

    419.60
    -0.54 (-0.13%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

BioCryst to Present at 40th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Monday, January 10, 2022 at 9:45 a.m. ET.

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com